SOURCE: Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.

May 13, 2015 17:30 ET

Pieris Pharmaceuticals Reports First Quarter 2015 Financial Results

Company to Host an Investor Conference Call on Thursday, May 14, 2015 at 10:00 AM EDT

FREISING, GERMANY--(Marketwired - May 13, 2015) - Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, reported today financial results for the first quarter ended March 31, 2015 and provided an update on the Company's recent developments.

"2014 was a year of significant progress for Pieris, both financially and in terms of therapeutic development and I am pleased to report that we continue to build on that momentum in 2015. We are progressing on our Phase I clinical trial for PRS-080, an anti-hepcidin Anticalin therapeutic protein designed to treat anemia, according to plan. We also are advancing our drug discovery and lead optimization efforts on numerous immunomodulatory targets, and progressing on several multispecific constructs in preclinical evaluation for immuno-oncology," commented Pieris' Chief Executive Officer, Stephen Yoder.

Corporate and Pipeline Highlights:

  • Jean-Pierre Bizzari, M.D., former Celgene and Sanofi Executive, appointed to the Board of Directors bringing extensive oncology drug development experience.
  • Phase I trial progression for PRS-080 remains on schedule with the final cohort of subjects planned to be enrolled by the middle of 2015 and reporting of results expected the second half of this year.
  • Pieris partner, the University of Melbourne, received a NHMRC grant totalling more than $AUS 500K to advance preclinical testing of PRS-060 for inhaled delivery to treat asthma.
  • Drug discovery and lead optimization efforts of PRS-300 for immuno-oncology continue to progress, with preclinical evaluation of several multispecifics constructs ongoing.

Financial Update:

Pieris reported a net loss of $3.7 million for the first quarter of 2015, compared to a net loss of $0.8 million for the first quarter of 2014. The results included non-cash, stock-based compensation expense of $0.5 million and $0.0 for the first quarter of 2015 and 2014, respectively. As of March 31, 2015, cash and cash equivalents totalled $13.2 million.

Total revenues were $0.2 million and $1.4 million for the three months ended March 31, 2015 and 2014, respectively. The quarter over quarter reduction in revenue was primarily attributable to the successful handover in 2014 of collaboration projects to our collaboration partners and no new collaboration milestone revenue recognized.

Research and development expenses were $1.5 million and $1.2 million for the three months ended March 31, 2015 and 2014, respectively. The $0.3 million increase in research and development expenses is primarily due to increased external clinical expenses associated with PRS-080 and increased internal expenses for PRS-300.

General and administrative expenses were $2.4 million and $0.8 million for the three months ended March 31, 2015 and 2014, respectively. The increase of $1.6 million in general and administrative expenses was due primarily to public company related costs, including $0.5 million in non-cash stock based compensation expense, legal and consulting expenses, and business development related expenses.

Conference Call:

Pieris' management will host a conference call beginning at 10:00 AM EDT on Thursday, May 14, 2015, to discuss the first quarter financial results and provide a corporate update. You can join the call by dialling +1-877-407-8920 (US & Canada) or +1-412-902-1010 (International) and providing the conference ID: 13603006. An archived replay of the call will also be available by dialling +1-877-660-6853 (US & Canada) or +1-201-612-7415 (International) and providing the conference ID: 13603006.

About Pieris:

Pieris is a clinical-stage biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high-unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. For more information visit

Anticalin®, Anticalins® are registered trademarks of Pieris.

Forward Looking Statements:
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the timing of our clinical trials or other development efforts, references to novel technologies and methods; our business and product development plans; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at, including without limitation our Current Report on Form 8-K dated December 17, 2014, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and the Company's Quarterly Reports on Form 10-Q.

Tables to Follow

ASSETS  March 31,  December 31,
   2015  2014
Current assets:        
 Cash and cash equivalents  $13,167,036  $18,474,211
 Other current assets   1,275,714   1,207,072
 Prepaid expenses   507,390   109,332
 Income tax receivable   15,232   14,810
 Total current assets   14,965,372   19,805,425
Property and equipment, net   1,785,789   2,052,221
Deferred tax asset   23,541   26,522
Total assets  $16,774,702  $21,884,168
   2015  2014
Current liabilities:           
 Trade accounts payable  $1,539,706   $1,260,015  
 Accrued expenses   413,395    743,866  
 Other current liabilities   274,255    242,755  
 Bank loan, including accrued interest   -    1,270,605  
 Deferred tax liabilities   23,541    26,522  
 Total current liabilities   2,250,897    3,543,763  
Accrued expenses, non-current   296,452    333,988  
Total liabilities   2,547,349    3,877,751  
Stockholders' equity           
 Common stock, $0.001 par value per share, 300,000,000 shares authorized and 29,429,522 and 29,279,522 issued and outstanding at March 31, 2015 and December 31, 2014   29,430    29,280  
 Additional paid-in capital   85,155,534    84,627,283  
 Accumulated other comprehensive loss   (1,445,829 )  (843,097 )
 Accumulated deficit   (69,511,782 )  (65,807,048 )
Total stockholders' equity   14,227,353    18,006,417  
Total liabilities and stockholders' equity  $16,774,702   $21,884,168  
   Three months ended March 31,
   2015  2014
Revenue  $217,621   $1,372,879  
Operating costs and expenses           
 Research and development   (1,524,631 )  (1,222,745 )
 General and administrative   (2,394,323 )  (821,351 )
    (3,918,954 )  (2,044,096 )
Loss from operations   (3,701,333 )  (671,217 )
Other income (expense)           
 Interest expense   (4,170 )  (109,289 )
 Other income, net   769    583  
Loss before income taxes   (3,704,734 )  (779,923 )
 Income tax benefit   -    18  
Net loss  $(3,704,734 ) $(779,905 )
Net loss per share           
 Basic and diluted  $(0.13 ) $(0.07 )
Weighted average number of common shares outstanding           
 Basic and diluted   29,292,855    11,828,974  

Contact Information